Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576547 | 0.83 | CLCN2 (0.55) | ALDH1A1LMNAAKR1C3AKR1C2KDM4E | |
| SCHEMBL7583004 | 0.82 | ALDH1A1 (0.42) | ALDH1A1LMNAKDM4ETDP1KMT2A | |
| SCHEMBL7573747 | 0.81 | F2 (0.46) | ALDH1A1LMNAKDM4ETDP1CLCN2 | |
| SCHEMBL7573910 | 0.80 | ATM (0.46) | ALDH1A1LMNAKDM4ETDP1KMT2A | |
| SCHEMBL7582466 | 0.78 | F2 (0.46) | ALDH1A1KDM4ECLCN2ATM | |
| SCHEMBL7573697 | 0.77 | CAMK2A (0.44) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL7598789 | 0.76 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4ETDP1KMT2A | |
| SCHEMBL7574221 | 0.75 | ALDH1A1 (0.44) | ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7576888 | 0.74 | CLCN2 (0.50) | ALDH1A1LMNACLCN2KMT2AMEN1 | |
| SCHEMBL7576854 | 0.73 | PTGS2 (0.51) | ALDH1A1LMNAAKR1C3AKR1C2CLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | ALDH1A1 942/4885LMNA 647/4885AKR1C3 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.